| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0071 |
0.9 |
| mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.007 |
0.9 |
| mRNA |
KW-2449 |
CTRPv2 |
pan-cancer |
AAC |
0.0063 |
0.9 |
| mRNA |
MLN4924 |
CTRPv2 |
pan-cancer |
AAC |
0.0072 |
0.9 |
| mRNA |
AMG-706 |
GDSC1000 |
pan-cancer |
AAC |
-0.0082 |
0.9 |
| mRNA |
BRD-K03536150 |
CTRPv2 |
pan-cancer |
AAC |
-0.0076 |
0.9 |
| mRNA |
AA-COCF3 |
CTRPv2 |
pan-cancer |
AAC |
-0.0073 |
0.9 |
| mRNA |
BRD-K13185470 |
CTRPv2 |
pan-cancer |
AAC |
-0.014 |
0.9 |
| mRNA |
ceranib-2 |
CTRPv2 |
pan-cancer |
AAC |
-0.0065 |
0.9 |
| mRNA |
lapatinib |
GDSC1000 |
pan-cancer |
AAC |
-0.01 |
0.9 |